Cargando…

Dengue virus type-3 envelope protein domain III; expression and immunogenicity

OBJECTIVE(S): Production of a recombinant and immunogenic antigen using dengue virus type-3 envelope protein is a key point in dengue vaccine development and diagnostic researches. The goals of this study were providing a recombinant protein from dengue virus type-3 envelope protein and evaluation o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fahimi, Hossein, Allahyari, Hossein, Hassan, Zuhair M, Sadeghizadeh, Majid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mashhad University of Medical Sciences 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328091/ https://www.ncbi.nlm.nih.gov/pubmed/25691924

Ejemplares similares

Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice
por: Fahimi, Hossein, et al.
Publicado: (2018)

In silico analysis of an envelope domain III-based multivalent fusion protein as a potential dengue vaccine candidate
por: Fahimi, Hossein, et al.
Publicado: (2016)

Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
por: Harahap-Carrillo, Indira S., et al.
Publicado: (2015)

Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III
por: Matsui, Kiyohiko, et al.
Publicado: (2010)

Diagnostic Performance of Dengue Virus Envelope Domain III in Acute Dengue Infection
por: Nguyen, Ngoc Minh, et al.
Publicado: (2019)

Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice
por: Chiang, Chen-Yi, et al.
Publicado: (2016)

DNA Vaccines against Dengue Virus Type 2 Based on Truncate Envelope Protein or Its Domain III
por: Azevedo, Adriana S., et al.
Publicado: (2011)

Molecular Changes in Dengue Envelope Protein Domain III upon Interaction with Glycosaminoglycans
por: Hyatt, James G., et al.
Publicado: (2020)

In silico binding analysis of lutein and rosmarinic acid against envelope domain III protein of dengue virus
por: Panchal, Ritesh, et al.
Publicado: (2021)

Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity
por: Park, Jisang, et al.
Publicado: (2020)

Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine
por: Wang, Xinyi, et al.
Publicado: (2019)

Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III
por: Ji, Guang-Hui, et al.
Publicado: (2015)

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
por: Arora, Upasana, et al.
Publicado: (2012)

Dengue Virus Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent NETosis-Mediated Inflammation in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III
por: Fan, Yi-Chin, et al.
Publicado: (2015)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
por: López-Camacho, César, et al.
Publicado: (2020)

Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies
por: Poddar, Ankur, et al.
Publicado: (2016)

Casamino acids facilitate the secretion of recombinant dengue virus serotype-3 envelope domain III in Pichia pastoris
por: Kaushik, Neha, et al.
Publicado: (2016)

A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III
por: Hu, Dan, et al.
Publicado: (2019)

Expression of an immunocomplex consisting of Fc fragment fused with a consensus dengue envelope domain III in Saccharomyces cerevisiae
por: So, Kum-Kang, et al.
Publicado: (2021)

Dengue virus 4/2 envelope domain chimeric virus panel maps type-specific responses against dengue serotype 2
por: Zhu, Deanna R., et al.
Publicado: (2023)

Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity
por: Diamos, Andrew G., et al.
Publicado: (2020)

Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins
por: Zidane, Nora, et al.
Publicado: (2013)

Production of tetravalent dengue virus envelope protein domain III based antigens in lettuce chloroplasts and immunologic analysis for future oral vaccine development
por: van Eerde, André, et al.
Publicado: (2019)

Epitope Presentation of Dengue Viral Envelope Glycoprotein Domain III on Hepatitis B Core Protein Virus-Like Particles Produced in Nicotiana benthamiana
por: Pang, Ee Leen, et al.
Publicado: (2019)

Exposure of Platelets to Dengue Virus and Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent Platelet Cell Death and Thrombocytopenia in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

Production of dengue 2 envelope domain III in plant using CPMV - based vector system
por: Carlos Marques, Lívia Érika, et al.
Publicado: (2014)

Dengue-1 Envelope Protein Domain III along with PELC and CpG Oligodeoxynucleotides Synergistically Enhances Immune Responses
por: Chiang, Chen-Yi, et al.
Publicado: (2012)

Exposure to Dengue Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent Endothelial Dysfunction and Hemorrhage in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies
por: Tripathi, Lav, et al.
Publicado: (2015)

Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4(+) T Cells to the Dengue Virus Envelope Protein Domain III
por: Zaneti, Arthur Baruel, et al.
Publicado: (2019)

A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies
por: Chua, Anthony JS, et al.
Publicado: (2013)

Evaluation of antibody response against recombinant domain III proteins of dengue virus type 1 and 2
por: Tripathi, Nagesh K, et al.
Publicado: (2017)

Simulation of Hemorrhage Pathogenesis in Mice through Dual Stimulation with Dengue Envelope Protein Domain III-Coated Nanoparticles and Antiplatelet Antibody
por: Lien, Te-Sheng, et al.
Publicado: (2023)

Phage Display Approaches for the Isolation of Monoclonal Antibodies Against Dengue Virus Envelope Domain III from Human and Mouse Derived Libraries
por: Moreland, Nicole J., et al.
Publicado: (2012)

Use of Envelope Domain III Protein for the Detection of IgG Type Antibodies Specific to Zika Virus by Indirect ELISA
por: Ndiaye, Oumar, et al.
Publicado: (2023)

Actin Interacts with Dengue Virus 2 and 4 Envelope Proteins
por: Jitoboam, Kunlakanya, et al.
Publicado: (2016)

Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies
por: Gallichotte, Emily N., et al.
Publicado: (2019)

Immunological Analysis of Nodavirus Capsid Displaying the Domain III of Japanese Encephalitis Virus Envelope Protein
por: Kumar, Kiven, et al.
Publicado: (2021)

Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_gjodpsdqr39tpi1hi2cft42pbh